NASDAQ:AGEN Agenus Q4 2025 Earnings Report $8.50 +0.10 (+1.19%) Closing price 04:00 PM EasternExtended Trading$8.44 -0.05 (-0.65%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Agenus EPS ResultsActual EPS$0.56Consensus EPS -$1.27Beat/MissBeat by +$1.83One Year Ago EPSN/AAgenus Revenue ResultsActual Revenue$34.20 millionExpected Revenue$28.10 millionBeat/MissBeat by +$6.11 millionYoY Revenue GrowthN/AAgenus Announcement DetailsQuarterQ4 2025Date3/16/2026TimeBefore Market OpensConference Call DateMonday, March 16, 2026Conference Call Time9:30AM ETUpcoming EarningsAgenus' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Agenus Earnings HeadlinesAgenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by AnalystsSeptember 23 at 4:45 AM | americanbankingnews.comAgenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh FinancingSeptember 20, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Chardan Capital Initiates Coverage on Agenus (NASDAQ:AGEN)September 20, 2026 | americanbankingnews.comChardan Initiates Agenus at Buy With $40 Price TargetSeptember 19, 2026 | marketscreener.comMLongeveron (NASDAQ:LGVN) and Agenus (NASDAQ:AGEN) Head to Head SurveySeptember 17, 2026 | americanbankingnews.comSee More Agenus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email. Email Address About AgenusAgenus (NASDAQ:AGEN) (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers. The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies. Among its investigational programs are botensilimab, an Fc-enhanced CTLA-4 antibody, and balstilimab, a PD-1 inhibitor. Agenus has evaluated these and other candidates in clinical studies across multiple cancer types, including colorectal cancer and other solid tumors. These products remain investigational unless approved by applicable regulatory authorities. Agenus was founded in 1994 and was formerly known as Antigenics before adopting the Agenus name in 2011. The company is headquartered in Lexington, Massachusetts, and conducts research and clinical development through operations and collaborations in the United States and internationally. Garo Armen, one of the company’s founders, serves as chairman and chief executive officer.View Agenus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
